Table 1.
Demographic, clinical and laboratory characteristics of 822 CKD stage 5 patients divided into four groups defined according to levels of serum albumin and hsCRP.
Table 2.
Univariate Spearman’s Rho correlations of S-albumin and hsCRP with other parameters in 822 patients with CKD stage 5.
Fig 1.
Association between S- albumin and subjective global assessment score (SGA) in 822 CKD stage 5 patients, according to inflammatory status.
Inflamed and non-inflamed were defined according to hsCRP concentrations above or below 3 mg/L.
Fig 2.
Kaplan-Meier survival curves during 60 months follow-up in 822 CKD stage 5 patients divided into four groups according to levels of hsCRP (high ≥3mg/L, or normal <3mg/L) and S-Alb (low <35 g/L, or normal ≥35g/L).
Group 1 (n = 200): Normal S-Alb and normal hsCRP; Group 2 (n = 160): Low S-Alb and normal hsCRP; Group 3 (n = 172): Normal S-Alb and high hsCRP; Group 4 (n = 290) Low S-Alb and high hsCRP.
Table 3.
All-cause mortality risk associated with low S-Alb <35 g/L and high hsCRP ≥3 mg/L (Group 4) during 60 months of follow-up.
Fig 3.
Inflammation/oxidative stress, resulting in hypoalbuminemia, interacts with cardiovascular disease (CVD) and protein-energy wasting (PEW) and together these changes contribute to the increased mortality in end-stage kidney disease.